The 2018 ASCO Annual Meeting featured the results of multiple large phase III trials aimed at establishing whether the use of PD-1/PD-L1 checkpoint inhibitors can enhance outcomes in metastatic non–small cell lung cancer (NSCLC).
Ongoing advancements in radiation oncology were among the highlights of the 2018 ASCO Annual Meeting. Approximately 80% of all patients with cancer receive radiation therapy as part of their treatment, Steven E. Finkelstein, MD, FACRO, of the Advanced Urology Institute, said.
In the following interview, the ASCO Daily News spoke with Stephen Leong, MD, of the University of Colorado School of Medicine, about immunotherapy’s progress in the field of gastrointestinal (GI) cancers and what he learned from abstracts presented during the 2018 ASCO Annual Meeting.
Several sessions during the 2018 ASCO Annual Meeting dealt with issues about survivorship and patient-reported outcomes. ASCO Daily News interviewed Don S. Dizon, MD, FACP, FASCO, of Lifespan Cancer Institute, about his key takeaways.
In the following interview, internationally renowned cancer researcher and medical oncologist Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, of Carolinas HealthCare System’s Levine Cancer Institute, details his views on the field of immunotherapy in bladder cancer.
The ASCO Daily News spoke recently with Edward S. Kim, MD, of the Carolinas Healthcare System Levine Cancer Institute, about key data presented during the 2018 ASCO Annual Meeting regarding drug activity across tumor types.
Inclusion of biologic factors in breast cancer staging in the American Joint Committee on Cancer (AJCC) eighth edition marks a significant change that highlights the importance of underlying tumor biology for staging.
Amidst the flood of immunotherapy trials being conducted in non–small cell lung cancer (NSCLC), interim data from two pivotal phase III trials of atezolizumab are beginning to inform if and how the anti–PD-L1 inhibitor may be used in the first-line setting.
The anti–PD-1 antibody pembrolizumab previously demonstrated superior overall survival (OS) in patients with advanced melanoma compared with ipilimumab in the phase III, multicenter randomized KEYNOTE-006 trial (NCT01866319).
Adding bevacizumab to the tyrosine kinase inhibitor (TKI) erlotinib significantly extended progression free-survival (PFS) in patients with late-stage or recurrent chemotherapy-naive EGFR-mutated non–small cell lung cancer (NSCLC) with good tolerability.
Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI). This agent was compared with gefitinib in the phase III open-label ARCHER1050 trial in patients with advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations.
Combination therapy with the oral BCL-2 inhibitor venetoclax plus a hypomethylating agent demonstrated a tolerable safety profile in elderly patients with untreated acute myeloid leukemia (AML) who were ineligible for standard induction chemotherapy.
In a small population of patients with advanced castration-resistant prostate cancer (CRPC), the anti–PD-1 inhibitor pembrolizumab had some anticancer activity, according to the results of KEYNOTE-199 (Abstract 5007) presented on June 4.